| __timestamp | Dynavax Technologies Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 21226345 |
| Thursday, January 1, 2015 | 86943000 | 87718074 |
| Friday, January 1, 2016 | 84493000 | 93831530 |
| Sunday, January 1, 2017 | 64988000 | 79419009 |
| Monday, January 1, 2018 | 74951000 | 132166913 |
| Tuesday, January 1, 2019 | 62331000 | 89124838 |
| Wednesday, January 1, 2020 | 28607000 | 65782137 |
| Friday, January 1, 2021 | 32228000 | 88845513 |
| Saturday, January 1, 2022 | 46600000 | 134715000 |
| Sunday, January 1, 2023 | 54886000 | 180142000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Dynavax Technologies Corporation have been at the forefront of this transformative journey. From 2014 to 2023, Intra-Cellular Therapies has consistently increased its R&D spending, culminating in a remarkable 750% growth by 2023. This surge underscores their commitment to pioneering new therapies. In contrast, Dynavax Technologies experienced a more fluctuating R&D trajectory, with a notable dip in 2020, reflecting strategic shifts in their research focus. By 2023, Dynavax's R&D expenses rebounded, marking a 35% increase from their 2020 low. These trends highlight the dynamic nature of biotech investments, where strategic pivots and sustained innovation drive long-term success. As these companies continue to push boundaries, their R&D endeavors promise to shape the future of healthcare.
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Analyzing R&D Budgets: Novartis AG vs Dynavax Technologies Corporation
Analyzing R&D Budgets: Zoetis Inc. vs Dynavax Technologies Corporation
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
BeiGene, Ltd. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Dynavax Technologies Corporation
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Comparing Innovation Spending: Vericel Corporation and Dynavax Technologies Corporation
Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?